DNA methylation profiles differ in responders versus non-responders to anti-PD-1 immune checkpoint inhibitors in patients with advanced and metastatic head and neck squamous cell carcinoma.

Starzer, AM; Heller, G; Tomasich, E; Melchardt, T; Feldmann, K; Hatziioan-nou, T; Traint, S; Minichsdorfer, C; Schwarz-Nemec, U; Nackenhorst, M; Mul-lauer, L; Preusser, M; Berghoff, AS; Fuereder, T.
J Immunother Cancer. 2022 Mar;10(3):e003420. doi: 10.1136/jitc-2021-003420.
https://pubmed.ncbi.nlm.nih.gov/35338086/